App Provides Immediate Access to Company News and Financial Information
EMERYVILLE, Calif., Jan. 15, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, has launched its Mobile Shareholder Smartphone investor application.
NovaBay's new Mobile Shareholder Smartphone application will be available for free download through Apple's App Store and Android's Google Play. The InvestorApp provides users with the ability to quickly obtain NovaBay's news, SEC filings, posters & publications, social media sites, media animations, the CEO's Blog and financial information via Smartphone or tablet with the touch of the NovaBay icon. Users who download the App will also be able to set-up push notification to alert them whenever NovaBay has released news, filed a report with the SEC or hit a price target that they have predetermined in the App's settings.
NovaBay also announced an updated and easier to use website at a new domain: www.NovaBay.com.
"The launch of NovaBay's innovative mobile application and updated website allows for us to more effectively communicate with our investment community," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "We are excited about the investor app, as it will provide direct and real-time mobile access to company news and financial information relevant to NovaBay. Thanks to Mobile Shareholder's proprietary technology, users are able to customize the application to their specific business needs on iPhone, iPad and Android."
NovaBay's Mobile Shareholder Smartphone investor application allows for its shareholders and investment community to have rapid availability to its financial data, press releases, events and conference participation, SEC filings, the CEO's blog, audio/video content and other related materials they wish to attain.
"Our new website address, NovaBay.com, makes us easier to find, and the site itself has been streamlined to enable interested parties to more efficiently seek information about the Company," concluded Dr. Najafi.
About NovaBay Pharmaceuticals, Inc.
Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of compounds, Aganocides® and NeutroPhase® Skin and Wound Cleanser. The Company's four core business units, DermaBay, UroBay, EyeBay and MediBay, are developing treatments that tackle infections in the dermatology, urology, ophthalmology, and wound care areas.
Aganocide® Compounds
NovaBay's first-in-class Aganocide compounds, led by NVC-422, are patented, topical antimicrobials with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides are not subject to bacterial or fungal resistance, which has been demonstrated in in-vitro and in-vivo studies. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay's clinical development activities are focused on three disease areas:
Dermatology – Partnered with Galderma, a leading dermatology company, to develop a formulation of NVC-422 for treatment of highly contagious skin infection, impetigo, which occurs most commonly in children. Enrollment into a global Phase 2b clinical study has begun and clinical data results are expected in second half 2013.
Ophthalmology – NovaBay is developing an eye drop formulation of NVC-422 for treating adenoviral conjunctivitis, a highly contagious viral eye infection for which there is no approved acute treatment. Enrollment into a global Phase 2b clinical study has begun, and clinical data results are expected in the second half of 2013.
Urology – NovaBay's urinary catheter irrigation solution containing NVC-422 is currently in a Phase 2b study, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and associated urinary tract infections. The Company reported positive data from the Phase 2a study and is evaluating the effect of an alternate more potent formulation of NVC-422 in Phase 2b. Results are expected in the first half of 2013.
NeutroPhase®
NeutroPhase is the only pure hypochlorous acid (HOCI) skin and wound cleanser cleared by the U.S. Food and Drug Administration (FDA) to target the six-million-patient U.S. market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers. The saline-based solution is the only wound cleanser on the market to include a stabilized, pure form of HOCl shown in studies to kill bacteria in solution, including flesh-eating bacteria. For additional information, visit: www.neutrophase.com.
Stay informed on NovaBay's progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website
Download our Mobile InvestorApp from the Apple Store or Google Play
Forward-Looking Statements
This release contains forward-looking statements, which are based upon NovaBay's current expectations, assumptions, estimates, projections and beliefs. Many of these statements are identified by the use of words denoting future events, such as "expect," "plan," "intend," "will," and variations of such words. These forward-looking statements include, but not limited to, NovaBay's plans and expectations regarding ongoing and future clinical trials, the timing of commencement and receiving results of clinical trials, and expected future financial results. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.